#EULAR2022 POS0199 showed marked decrease in SARS-CoV2 IgG ab 6 months after initial two dose vaccines. @RheumNow https://t.co/lZdWQUqFvf

Are JAKi fulfilling their promises in RA? H Schulz-Koops said a survey showed rheumatologists wanted effective fast acting Rx that could be used as monotherapy. ⁦⁦@eular_org⁩ #EULAR2022 ⁦@RheumNow⁩ https://t.co/Gdel9YnAzA

More data on #iberdomide… from phase 2 study --looks like it helps #SCLE and #CCLE (but not for #ACLE) Dr. V Werth #EULAR2022 @rheumnow https://t.co/FYZlB219lf

Potential new target anti-BDCA2 Ab, #litifilimab targets pDC… impressive phase 2 studies with sig improvement in CLASI-A scores #EULAR2022 @rheumnow https://t.co/hJGx3c3Fbb

#OP0252 #EULAR2022 Dr Yeoh presented data from Global Rheum Alliance of >300 pts with myositis. 13% died. Usual suspects re: Factors assoc with poor #COVID outcome: age, active disease,on steroid,male and RTX exposure. Be interesting to see longer followup post-booster @RheumNow https://t.co/F7qaee5ADK

#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/u9KkZrUKGo

#PEARLS by Dr. Werth: 1. anti-malarials only work 50% of time for cutaneous lupus (CLE). 2. AZP is not as effective as MTX or MMF for #CLE 3. Consider RTX refractory #bullous lupus #EULAR2022 @rheumnow https://t.co/6FPJEGWioJ

VIGIBASE registry RA 39000+ pts JAKi and 231000+ pts TNFi *No increase in MACEs with JAKi 1.4% vs. 0.9% *JAKi Increase in DVT RR 3.99 and PE RR 3.5 adjusted on age and sex @RheumNow #OP0268 #EULAR2022 #Lupus https://t.co/hiAvKctgky

Some / most of promises of #JAKi are fulfilled. Efficacy, adherence = on mono vs combination Rx with MTX. But some emerging safety issues. NK cells reduce inflammation of NK cells on fibroblasts re other MOA. @eular #EULAR2022 ⁦@RheumNow⁩ The promise of #JAKi I RA https://t.co/8Ry3vVMyzO

Gilbert et al. RA assoc increased risk hospitalisation or death from COVID-19 1.53 (1.20, 1.94). RA-ILD assoc even greater risk hospitalisation or death multivariable HR 2.84 [95% CI 1.64-4.91] @RheumNow #EULAR2022 OP0251 https://t.co/h1jzAV6xNR https://t.co/7E1EzAKCDv